Additionally, a once‐weekly option might facilitate treatment initiation in T2D individuals who have not previously taken insulin by minimising clinical inertia and promoting higher acceptance of insulin therapy [16]. The gene discussed is INS; the disease is type 2 diabetes mellitus.